As TLR4 activation in myeloma cells suppresses ER stress, reducing the efficacy of BTZ [22], we evaluated herein the role of TLR4 signalling on MM cells’ mitochondrial dynamics and energy metabolism as the potentially active mechanism of drug resistance to BTZ. This evidence concerns the gene TLR4 and plasma cell myeloma.